Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: A report from the acute leukemia working party of the EBMT

Marie T. Rubio, Bipin N. Savani, Myriam Labopin, Simona Piemontese, Emmanuelle Polge, Fabio Ciceri, Andrea Bacigalupo, William Arcese, Yener Koc, Dietrich Beelen, Zafer Gülbas, Depei Wu, Stella Santarone, Johanna Tischer, Boris Afanasyev, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Arnon Nagler

Risultato della ricerca: Contributo in rivistaArticolo in rivista

42 Citazioni (Scopus)


Background: Increasing numbers of patients are receiving haplo-identical stem cell transplantation (haplo-SCT) for treatment of acute leukemia with reduced intensity (RIC) or myeloablative (MAC) conditioning regimens. The impact of conditioning intensity in haplo-SCT is unknown. Methods: We performed a retrospective registry-based study comparing outcomes after T-replete haplo-SCT for patients with acute myeloid (AML) or lymphoid leukemia (ALL) after RIC (n = 271) and MAC (n = 425). Regimens were classified as MAC or RIC based on published criteria. Results: A combination of post-transplant cyclophosphamide (PT-Cy) with one calcineurin inhibitor and mycophenolate mofetil (PT-Cy-based regimen) for graft-versus-host disease (GVHD) prophylaxis was used in 66 (25 %) patients in RIC and 125 (32 %) in MAC groups. Patients of RIC group were older and had been transplanted more recently and more frequently for AML with active disease at transplant. Percentage of engraftment (90 vs. 92 %; p = 0.58) and day 100 grade II to IV acute GVHD (24 vs. 29 %, p = 0.23) were not different between RIC and MAC groups. Multivariable analyses, run separately in AML and ALL, showed a trend toward higher relapse incidence with RIC in comparison to MAC in AML (hazard ratio (HR) 1.34, p = 0.09), and no difference in both AML and ALL in terms of non-relapse mortality (NRM) chronic GVHD and leukemia-free survival. There was no impact of conditioning regimen intensity in overall survival (OS) in AML (HR = 0.97, p = 0.79) but a trend for worse OS with RIC in ALL (HR = 1.44, p = 0.10). The main factor impacting outcomes was disease status at transplantation (HR ≥ 1.4, p ≤ 0.01). GVHD prophylaxis with PT-Cy-based regimen was independently associated with reduced NRM (HR 0.63, p = 0.02) without impact on relapse incidence (HR 0.99, p = 0.94). Conclusions: These data suggest that T-replete haplo-SCT with both RIC and MAC, in particular associated with PT-Cy, are valid options in first line treatment of high risk AML or ALL.
Lingua originaleEnglish
pagine (da-a)25-25
Numero di pagine1
Stato di pubblicazionePubblicato - 2016


  • Acute Disease
  • Acute Leukemia
  • Adult
  • Allogeneic stem cell transplantation
  • Anti-leukemic effect
  • Antineoplastic Combined Chemotherapy Protocols
  • Cancer Research
  • Conditioning regimen
  • Cyclophosphamide
  • Cytarabine
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease
  • Haplo-identical donor
  • Hematology
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid
  • Male
  • Melphalan
  • Middle Aged
  • Molecular Biology
  • Multivariate Analysis
  • Mycophenolic Acid
  • Neoplasm Recurrence, Local
  • Oncology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Retrospective Studies
  • Toxicity
  • Transplantation Conditioning
  • Treatment Outcome


Entra nei temi di ricerca di 'Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: A report from the acute leukemia working party of the EBMT'. Insieme formano una fingerprint unica.

Cita questo